Skip to main content
SpringerLink
Log in

Are autologous bone marrow stem cell transplantation and transcatheter arterial embolization the best choices for patients with hepatocellular carcinoma and hepatic dysfunction? Report of a case

  • Case Report
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

The purpose of this work was to evaluate the effects of autologous bone marrow stem cell transplantation (AMSCT) and transarterial embolization (TAE) in patients with hepatocellular carcinoma (HCC) and hepatic dysfunction. A 58-year-old male with HCC and hepatic function of Child’s class C was treated with 8 ml of a lipiodol emulsion by injection into the artery feeding of his tumor, and >108 bone marrow stem cells were isolated from 400 ml bone marrow and then injected into the right hepatic artery. The patient’s laboratory examinations revealed a progressive decrease in total bilirubin (from 264.8 to 77.9 μmol/L) and direct bilirubin (from 222.0 to 59.7 μmol/L) after 1 month, and a repeat CT showed that most of the tumor was filled with lipiodol. The combined treatment using AMSCT and TAE is a good choice of treatment for HCC patients who are unable to tolerate TACE due to hepatic dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Yang JD, Kim WR, Coelho R. Cirrhosis is present in most patients with Hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:64–70.

    Article  PubMed  Google Scholar 

  2. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19:271–85.

    Article  PubMed  CAS  Google Scholar 

  3. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.

    Article  PubMed  Google Scholar 

  4. Trevisani S, Notariis De, Rossi C, Bernardi M. Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies? J Clin Gastroenterol. 2001;32:383–9.

    Article  PubMed  CAS  Google Scholar 

  5. Lagasse E, Connors H, Al-Dhalimy M, Reitsma M, Dohse M, Osborne L, et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med. 2000;6:1229–34.

    Article  PubMed  CAS  Google Scholar 

  6. Rabani V, Shahsavani M, Gharavi M, Piryaei A, Azhdari Z, Baharvand H, et al. Mesenchymal stem cell infusion therapy in a carbon tetrachloride-induced liver fibrosis model affects matrix metalloproteinase expression. Cell Biol Int. 2010;34:601–5.

    Article  PubMed  Google Scholar 

  7. Lyra AC, Soares MB, da Silva LF, Fortes MF, Silva AG, Mota AC, et al. Feasibility and safety of autologous bone marrow mononuclear cell transplantation in patients with advanced chronic liver disease. World J Gastroenterol. 2007;13:1067–73.

    PubMed  CAS  Google Scholar 

  8. Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells. 2006;24:2292–8.

    Article  PubMed  CAS  Google Scholar 

  9. Salama H, Zekri AR, Zern M, Bahnassy A, Loutfy S, Shalaby S, et al. Autologous hematopoietic stem cell transplantation in 48 patients with end-stage chronic liver diseases. Cell Transplant. 2010;19:1475–86.

    Article  PubMed  Google Scholar 

  10. Pai M, Zacharoulis D, Milicevic MN, Helmy S, Jiao LR, Levicar N, et al. Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol. 2008;103:1952–8.

    Article  PubMed  CAS  Google Scholar 

  11. Khan AA, Shaik MV, Parveen N, Rajendraprasad A, Aleem MA, Habeeb MA, et al. Human fetal liver-derived stem cell transplantation as supportive modality in the management of end-stage decompensated liver cirrhosis. Cell Transplant. 2010;19:409–18.

    PubMed  Google Scholar 

  12. Gilchrist ES, Plevris JN. Bone marrow-derived stem cells in liver repair: 10 years down the line. Liver Transpl. 2010;16:118–29.

    Article  PubMed  Google Scholar 

  13. Houlihan DD, Newsome PN. Critical review of clinical trials of bone marrow stem cells in liver disease. Gastroenterology. 2008;135:438–50.

    Article  PubMed  CAS  Google Scholar 

  14. Khan AA, Parveen N, Mahaboob VS, Rajendraprasad A, Ravindraprakash HR, Venkateswarlu J, et al. Safety and efficacy of autologous bone marrow stem cell transplantation through hepatic artery for the treatment of chronic liver failure: a preliminary study. Transplant Proc. 2008;40:1140–4.

    Article  PubMed  CAS  Google Scholar 

  15. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med. 2006;203:1235–47.

    Article  PubMed  CAS  Google Scholar 

  16. Zhu W, Xu W, Jiang R, Qian H, Chen M, Hu J, et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol. 2006;80:267–74.

    Article  PubMed  CAS  Google Scholar 

  17. Ismail A, Aldorry A, Shaker M, Elwekeel R, Mokbel K, Zakaria D, et al. Simultaneous injection of autologous mononuclear cells with TACE in HCC patients; preliminary study. J Gastrointest Cancer. 2011;42:11–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

The research was granted by CSTC: 2008BB5118.

Conflict of interest

None of the authors has any conflict of interest with regard to the paper.

Author information

Authors and Affiliations

  1. Department of Hepatobiliary Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China

    Xiao-bing Huang, Xi-wen Wang, Jing Li, Lu Zheng, Hong-zi Zhao, Ping Liang & Ji-gang Dai

Authors
  1. Xiao-bing Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xi-wen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lu Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hong-zi Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ping Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ji-gang Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ping Liang or Ji-gang Dai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, Xb., Wang, Xw., Li, J. et al. Are autologous bone marrow stem cell transplantation and transcatheter arterial embolization the best choices for patients with hepatocellular carcinoma and hepatic dysfunction? Report of a case. Surg Today 42, 1225–1228 (2012). https://doi.org/10.1007/s00595-011-0107-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-011-0107-3

Keywords

Search

Navigation